Overview
- Researchers at Washington University in St. Louis built mathematical models that translate an individual's blood p‑tau217 level into an estimated time to first Alzheimer symptoms.
- The approach was trained and tested in two independent cohorts (Knight ADRC, n=258, median age 67.7; ADNI, n=345, median age 72.7) followed with serial blood tests and clinical assessments.
- Prediction accuracy held at roughly 3 to 3.7 years when models were applied across cohorts and across five commercial assay versions, including one cleared by the U.S. FDA.
- Age strongly altered timelines in the models, with a similar protein threshold corresponding to about 20 years to symptoms at age 60 versus roughly 11 years at age 80.
- Scientists caution that forecasts are most reliable only in the mid‑range of values and are unsuitable for asymptomatic screening, while parallel coverage highlights early symptom checks, prevention habits, and an estimated 1.8 million people living with Alzheimer’s in Germany.